Phase 2 data for efdoralprin alfa demonstrate the recombinant protein maintains normal protein levels with less frequent dosing than current standards of care for patients with alpha-1 antitrypsin deficiency (AATD)-related emphysema.
Phase 2 data for efdoralprin alfa demonstrate the recombinant protein maintains normal protein levels with less frequent dosing than current standards of care for patients with alpha-1 antitrypsin deficiency (AATD)-related emphysema.
Read More
A newly discovered biological process protects liver cells from protein buildup in patients with alpha-1-antitrypsin deficiency.
Read More
Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in a phase 2 clinical trial for adults with alpha-1 antitrypsin deficiency emphysema.
Read More
Combining Alpha-1 antitrypsin deficiency (AAT/AATD) assays allowed a multitiered AATD testing algorithm to improve diagnosis.
Read More
The European Respiratory Society Congress featured two abstracts using data from the Bronchiectasis and NTM Research Registry.
Read More
Prime Medical will use its gene editing platform to correct the gene mutations that lead to alpha-1 antitrypsin deficiency (AATD) lung disease and liver disease.
Read More
Despite certain study participants having lower risk factors associated with developing cardiovascular disease, including being younger and a higher proportion who had never smoked, 12.7% of participants developed cardiovascular disease after four years of follow-up.
Read More
The risk of developing COPD could be 50% greater for women as it is for men, according to a new diagnostic method utilized by researchers from Lund University Sweden.
Read More
Compared to COPD, asthma, or cystic fibrosis, Alpha-1 antitrypsin deficiency lung disease is not well known, but dedicated researchers and RTs continue to support patients and work towards finding new treatment options.
Read More
Individuals with single-gene mutations that decrease levels of the protein alpha-1 antitrypsin are at high risk for emphysema at a young age. Researchers have attained sustained in vivo expression of normal human alpha-1 antitripsin—and at levels that improved emphysema in mice.
Read More
Thanks to the Alpha-1 Foundation, many COPD patients with alpha-1 antitrypsin deficiency have been properly diagnosed and treated, but the work is far from over.
Read More
For the 12th year in a row, US News & World Report named National Jewish Health, Denver, the best respiratory hospital in the nation.
Read More
A higher than expected number of COPD and asthma patients had abnormally low levels of alpha-1 antitrypsin.
Read More
RT spoke with ZLB Behring, the company that manufactures the alpha-1 therapy Zemaira, to gain a better understanding of alpha-1 and the treatments available.
Read More
Air travel is complicated for oxygen-dependent people, involving fees that can double the cost of the ticket and periods of time without access to oxygen. Patient and professional advocacy efforts might help.
Read More
